Cancer News and Research

Latest Cancer News and Research

Brazilian breast cancer drug market to grow from $424M in 2009 to $611M in 2014: Decision Resources

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the breast cancer drug market in Brazil will grow from $424 million in 2009 to $611 million in 2014. Factors promoting the market's growth include steady increases in the number of incident breast cancer cases, shifts toward higher-cost chemotherapy and hormonal regimens in the adjuvant setting and increases in the use of targeted therapies following novel product launches and label extensions.

16 Jun 2010

RG7204 holds promise for metastatic melanoma with V600E BRAF mutation

Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma.

16 Jun 2010

AssureImmune merges with BCU

AssureImmune LLC, the premier family stem cell bank in the United States, today announced their merger with Banco de Cordón Umbilical, the largest cord blood bank in Latin America. This merger expands the Companies' global reach providing family stem cell banking services to North, Central and South America.

16 Jun 2010

Life Technologies forms GIBCO Cell Therapy Systems

Life Technologies Corporation today announced the formation of GIBCO® Cell Therapy Systems (CTS™), which will offer the life science industry's widest array of products to support cell therapy applications, including regenerative medicine. Specifically designed to help cell therapy practitioners accelerate the transition from research to clinical applications, the product portfolio will include a broad and deep offering of Invitrogen devices and reagents.

16 Jun 2010

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

UCB and Immunomedics Inc. announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEM™, showed the clinical efficacy of epratuzumab in patients with SLE.

16 Jun 2010

Predictive Biosciences completes $25M Series C financing round

Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced the completion of a $25 million Series C round of growth capital financing. New investor ProQuest Investments led the round, joined by all current investors: Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

16 Jun 2010

Report reveals increase in patients influence on success, failure of new drugs

Patients are emerging as an increasingly strong group when it comes to influencing the success and failure of new drugs - according to a newly published New Health Report commissioned by Quintiles to gauge the opinions of biopharma executives, managed care executives and patients, and to track progress in the New Health.

16 Jun 2010

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday.

16 Jun 2010

Researchers study science and clinical treatment of FAS

It's long been known that alcohol use in pregnancy can lead to children with mental retardation and birth defects, but researchers who study fetal alcohol syndrome have not made definitive progress on preventing the disorder, detecting it early, or effectively treating it, say researchers from Georgetown University Medical Center.

16 Jun 2010

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

Identification of a key player in a signaling pathway involved in the development of melanoma - the deadliest form of skin cancer - may offer hope for new targeted melanoma therapies.

16 Jun 2010

UNC researchers study why surgery happens less often in blacks with lung cancer

A new study led by UNC researchers that looks at newly diagnosed lung cancer patients and follows them from diagnosis forward is one of the first to give reasons why patients don't go to lung surgery and why surgery happens less often in blacks.

16 Jun 2010

Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma

Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fourth scheduled safety analysis and recommended that the trial continue per the protocol.

16 Jun 2010

New online smoking-cessation study launched

Fred Hutchinson Cancer Research Center announced today that it is launching a new online study to help people quit smoking. The study, called WebQuit, is enrolling adult smokers nationwide. Participation is free to eligible individuals.

16 Jun 2010

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.

16 Jun 2010

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

16 Jun 2010

Study demonstrates mechanism behind hijacking of TNF controlled response to tumours

Cancer Research UK scientists have discovered how two genes can 'hijack' control of part of the body's defences against cancer, helping them grow and spread.

16 Jun 2010

Study examines survival rates of CF patients with MRSA

A team of researchers led by Elliott Dasenbrook, MD, MHS, Assistant Professor of Medicine and Pediatrics at Case Western Reserve University School of Medicine and Associate Director of the Adult Cystic Fibrosis Program at University Hospitals Case Medical Center's Rainbow Babies & Children's Hospital today published the findings from a major study about cystic fibrosis survival rates in the June 16 issue of JAMA.

16 Jun 2010

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Acclaimed virologist Robert Webster, Ph.D., of St. Jude Children's Research Hospital, presented the 2010 Leeuwenhoek prize lecture today, a prestigious recognition awarded by the Royal Society in London.

16 Jun 2010

Exercise helps patients recover shoulder movement after breast cancer surgery

An active 72-year-old woman, Claire Mitchell had always enjoyed cooking. However, after breast cancer surgery she found that she had less freedom of movement and reaching jars on high shelves became quite painful. Her plight is common.

16 Jun 2010

Apollo Health Street announces second agreement with MCHS

Apollo Health Street, a developer of world-class solutions that tackle healthcare's toughest financial and IT challenges, announced today a second agreement with Mississippi County Hospital System which comprises two hospitals - SMC Regional Medical Center in Osceola, AR and Great River Medical Center in Blytheville, AR.

16 Jun 2010

Cancer News and Research

Latest Cancer News and Research

Brazilian breast cancer drug market to grow from $424M in 2009 to $611M in 2014: Decision Resources

RG7204 holds promise for metastatic melanoma with V600E BRAF mutation

AssureImmune merges with BCU

Life Technologies forms GIBCO Cell Therapy Systems

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

Predictive Biosciences completes $25M Series C financing round

Report reveals increase in patients influence on success, failure of new drugs

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

Researchers study science and clinical treatment of FAS

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

UNC researchers study why surgery happens less often in blacks with lung cancer

Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma

New online smoking-cessation study launched

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

Study demonstrates mechanism behind hijacking of TNF controlled response to tumours

Study examines survival rates of CF patients with MRSA

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Exercise helps patients recover shoulder movement after breast cancer surgery

Apollo Health Street announces second agreement with MCHS

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in